170
Views
6
CrossRef citations to date
0
Altmetric
Research Article

A 26-week repeated-dose toxicity study of allisartan isoproxil in Sprague-Dawley rats

, , , , , , , & show all
Pages 443-450 | Received 10 Aug 2012, Accepted 12 Dec 2012, Published online: 27 Mar 2013

References

  • Baylis C. (1994). Age-dependent glomerular damage in the rat. Dissociation between glomerular injury and both glomerular hypertension and hypertrophy. Male gender as a primary risk factor. J Clin Invest 94:1823–9
  • Cesare C, Francesca N, Alberto Z. (2008). Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention. Vasc Health Risk Manag 4:67–73
  • Gian PR. (2009). Losartan metabolite EXP3179: an AT1-receptor-independent treatment strategy for patients with the metabolic syndrome? Hypertension 54:710–12
  • Hard GC, Johnson KJ, Cohen SM. (2009). A comparison of rat chronic progressive nephropathy with human renal disease—implications for human risk assessment. Crit Rev Toxicol 39:332–46
  • Hard GC, Khan KN. (2004). A contemporary overview of chronic progressive nephropathy in the laboratory rat, and its significance for human risk assessment. J Toxicol Pathol 32:171–80
  • Hiromichi S, Hidetomo N, Hirokazu O, et al. (2003). A selective angiotensin receptor antagonist, valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. Adv Perit Dial 19:59–72
  • Kjeldsen SE, Strand A, Julius S, Okin PM. (2006). Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy. J Clin Hypertens (Greenwich) 8:487–92
  • Masatoyo K, Ichiro S, Tsutomu Y, et al. (1994). Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation 89:2204–11
  • Obayashi M, Yano M, Kohno M, et al. (1997). Dose-dependent effects of ANG II-receptor antagonist on myocyte remodeling in rat cardiac hypertrophy. Am J Physiol Heart Circ Physiol 273:H1824–31
  • Product Monograph of ARACAND®, Candesartan Cilexetil, AstraZeneca Canada Inc
  • Product Monograph (994-a, 2, 06) of COZAAR®, Losartan potassium tablets, Merck Frosst Canada Ltd
  • Seely JC, Hard GC. (2008). Chronic progressive nephropathy (CPN) in the rat: review of pathology and relationship to renal tumorigenesis. J Toxicol Pathol 21:199–205
  • Shibasaki Y, Masaki H, Nishiue T, et al. (2002). Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventrivular hypertrophy in end-stage renal disease. Nephron 90:256–61
  • Sica DA, Gehr TW, Ghosh S. (2005). Clinical pharmacokinetics of losartan. Clin Pharmacokinet 44:797–814
  • Tanaka A, Kyokuwa M, Mori T, Kawashima S. (1995). Acceleration of renal dysfunction with aging by use of androgen in Wistar/Tw rats. In Vivo 9:495–502
  • Thürmann PA, Kenedi P, Schmidt A, et al. (1998). Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 98:2037–42
  • Timmermans PB, Wong PC, Chiu AT, et al. (1993). Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45:205–51

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.